key: cord-0981123-sqnr7d3y authors: Aljabr, Waleed; Al-Amari, Ahod; Abbas, Basma; Karkashan, Alaa; Alamri, Saad; Alnamnakani, Mohammed; Al-Qahtani, Athba title: Evaluation of the Levels of Peripheral CD3(+), CD4(+), and CD8(+) T Cells and IgG and IgM Antibodies in COVID-19 Patients at Different Stages of Infection date: 2022-02-23 journal: Microbiol Spectr DOI: 10.1128/spectrum.00845-21 sha: eff94bce7896307f8c3b76dcf1d48d6e9ddb14da doc_id: 981123 cord_uid: sqnr7d3y Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection affects the stimulatory levels of cellular-mediated immunity, which plays an essential role in controlling SARS-CoV-2 infection. In fact, several studies have shown the association of lymphopenia with severe COVID-19 in patients. The aim of this study is to investigate the response of the immune system, including cell-mediated immunity and antibody production, during different stages of SARS-CoV-2 infection. Peripheral blood and serum samples were collected from patients with moderate infection, patients under medication (hospitalized), patients who had recovered, and healthy individuals (n = 80). Flow cytometry analysis was performed on peripheral blood samples to determine the cellular immunity profile of each patient. The data showed a significant reduction in the levels of CD3(+), CD4(+), and CD8(+) T cells and CD45(+) cells in the moderate and under-medication groups, suggesting lymphopenia in those patients. Also, enzyme-linked immunosorbent assay (ELISA) was conducted on the serum samples to measure the levels of antibodies, including IgM and IgG, in each patient. The results revealed a significant increase in the levels of IgM in the moderate infection and under-medication patients, thus indicating the production of IgM during the first week of infection. Furthermore, changes in the levels of IgG were significantly detected among recovered patients, indicating therefore a remarkable increase during the recovery stage of SARS-CoV-2 infection and thus a strong humoral-mediated immunity. In summary, the results of this study may help us to understand the main role of the cellular immune responses, including CD3(+), CD4(+), and CD8(+) T cells, against SARS-CoV-2 infection. This understanding might support the development of SARS-CoV-2 treatments and vaccines in the near future. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China. This virus is a serious threat to people not only in China but also worldwide, where it has been detected in over 222 countries. It has been reported that ∼3.4% of SARS-CoV-2-infected patients have died. The significance of our study relies on the fact that an enzyme-linked immunosorbent assay and flow cytometry were used to measure the levels of antibodies and cellular immune response, respectively, from clinical samples of patients infected with SARS-CoV-2. during viral infections, including coronavirus (25, 26) , their levels were determined in each patient's sample. Flow cytometry analysis was performed on all of the blood cells from all categories except the healthy category, in which only 15 samples were included, to generate the profile and levels of immune cells subsets in each sample. The level of immune cells was evaluated by calculating the median percentage of cells obtained from each sample. Then, a correlation between the level of immune cells and different groups' status (categories) was determined. The results revealed different levels of CD3 1 , CD4 1 , CD8 1 , CD16 1 CD56 1 , CD19 1 , and CD45 1 between the groups. Also, the results showed different ratios of CD4 1 to CD8 1 T cells: this ratio compares the portion of helper CD4 1 T cells to killer CD8 1 T cells. As shown in Table 1 and Fig. 1 , significant differences in the levels of CD3 1 , CD4 1 , CD8 1 , and CD45 1 cells between the study groups (P , 0.05 by analysis of variance [ANOVA]) were observed. The cells were significantly higher in the healthy group compared to the moderate infection and under-medication individuals. However, there was an insignificant difference in the levels of CD3 1 cells between the healthy and recovered patients (P , 0.05 by Tukey's honestly significant difference [HSD] post hoc test) ( Table 2 and Fig. 1 ). Regarding the other components of the immune profile, including CD16 1 , CD56 1 , CD19 1 , and CD4 1 /CD8 1 T cell ratio, the data show an insignificant difference between the study groups, as shown in Tables 1 and 2 and Fig. 1 (P , 0.05 by ANOVA) (P , 0.05 by Tukey's HSD post hoc test). Furthermore, a correlation matrix plot was used to assess the level of correlation between different immune cells. A strong correlation was found between CD4 1 and CD45 1 cells, CD3 1 and CD4 1 cells, CD8 1 cells, and CD45 1 cells. Correlations were also found with CD8 1 and CD4 1 cells and CD45 1 cells. In addition, a correlation was observed between CD19 1 and CD45 1 cells, as shown in Fig. S1 in the supplemental material. The results revealed that CD3 1 , CD4 1 , CD8 1 , CD45 1 , and CD19 1 cells had a strong relationship and high level of correlation with each other in a specific manner as a response to SARS-CoV-2 infection. Antibody production. In addition to the T cell response, production of IgG and IgM antibodies against SARS-CoV-2 infection were investigated in this study by enzyme-linked immunosorbent assay (ELISA). ELISA is a serological test used to detect the presence of the immunoglobulins IgG and IgM against SARS-CoV-2 (27, 28) , targeting the spike and nucleocapsid proteins (S and N, respectively). Four categories were involved and included the following numbers of patients: 20 who were healthy, 20 with moderate infection, 20 under medication, and 20 who had recovered. As seen in Fig. 2 , the levels of IgM in the moderate infection, under-medication, and recovered groups were significantly higher than those in the healthy group (P , 0.001 by ANOVA). Although IgM levels showed an insignificant difference between the moderate infection and under-medication groups, both had significantly higher levels than the recovered individuals (P , 0.001 by ANOVA). IgG, on the other hand, has shown similar results to IgM in terms of their presence across the categories. IgG levels were significantly lower in the healthy group compared to the other groups, including the individuals in the moderate infection, under-medication, and recovered groups (Fig. 2) (P , 0.001 by ANOVA). Although IgG levels in the moderate infection and under-medication groups were significantly higher than those in the healthy group, they were significantly lower than those in the recovered individuals (P , 0.001 by ANOVA). The levels of IgG in the moderate infection group showed a significant decrease compared to the undermedication group as well as the recovered group. The IgG levels in the under-medication group were significantly higher than in the moderate infection group but significantly lower than those in the recovered group (P , 0.001 by ANOVA). Finally, patients who have recovered from COVID-19 showed the highest level of IgG in comparison to the other groups (P , 0.001 by ANOVA). Interestingly, the levels of IgG antibody in the recovered, moderate infection, and under-medication groups were higher than IgM antibody levels in the same groups. Moreover, the levels of IgG increased as the recovery state developed from healthy, to moderate infection, to under medications, to recovered. The recovered group exhibited the highest levels of IgG immunity after infection among different groups, thus indicating an increase in the levels of memory immunity, as illustrated in Fig. 3 . The levels of IgM, on the other hand, decreased as recovery advanced. The levels of IgM were higher in the moderate infection group and decreased as the patients were recovering (Fig. 3) . In summary, we could determine the role of CD3 1 , CD4 1 , and CD8 1 T cells, as well as CD45 1 cells, as they showed impaired cellular immunity in infected patients. The results for IgM and IgG antibodies indicated, on the other hand, a strong humoral immune response in SARS-CoV-2 patients. 1 , and CD4 1 /CD8 1 T cell ratio) of the study group was evaluated using flow cytometry. The box plot shows the data distribution and shows the outliers. The line in the middle represents the median of the percentage of cells obtained from each sample. Results were considered significant at P , 0.05. Cellular immune responses play an essential role in virus clearance and disease severity (29) (30) (31) . One study on SARS-CoV has demonstrated the requirement of specific T cell responses for the treatment of SARS-CoV-infected mice (29) . In addition, several studies have shown that cell-mediated immunity, mainly cytotoxic (CD8 1 ), is an essential factor in eliminating numerous virus-infected cells during severe infections (reviewed in reference 26). On the other hand, a study has demonstrated that depletion of helper T cells (CD4 1 ) in SARS-Cov-infected mice increases the duration of viral clearance, whereas there was no effect when CD8 1 T cells were depleted (30) . This indicates the important role of CD4 1 T cells in controlling SARS-Cov infection, as well as other viral infections (30, 32) . Specific CD4 1 T cells were detected in peripheral blood samples of COVID-19 patients (33) . Several studies have investigated the T cell responses of COVID-19 patients; however, most of them were performed on a single patient or small number of patients (7) . Besides, information regarding the correspondence between levels of T cell responses (CD4 1 and CD8 1 ) during different COVID-19 stages is scarce-hence the importance of this study. This study was performed using peripheral blood samples from 80 individuals with different stages of COVID-19. Flow cytometry was used to detect the populations of CD4 1 CD8 1 and CD3 1 T cells. Also, specific IgM and IgG antibodies were detected using ELISA. Differences were observed with population levels of CD4 1 CD8 1 and CD3 1 T cells at different stages of SARS-CoV-2 infection. The results of the current study indicated a significant reduction in the levels of CD3 1 , CD4 1 , and CD8 1 T cells in the moderate infection and under-medication groups compared to the healthy group. This finding is in agreement with what was observed by previous studies, as the results showed a low count of CD3 1 , CD4 1 , and CD8 1 T cells in COVID-19 patients, particularly in moderate and severe cases (20, 34, 35) . However, the recovered COVID-19 patients in this study showed an increase in CD3 1 , CD8 1 , and CD4 1 T cell levels in comparison to the moderate infection and under-medication groups. Therefore, it can be deduced that SARS-CoV-2 infection could affect T cell population counts in the peripheral blood, most frequently with severe cases (11, 34) . When the T cell levels were compared between the group that recovered from COVID-19 and healthy controls, they showed an insignificant difference. Restoration of T cells in the recovered patients could probably be an indication of viral clearance (16) . Moreover, the CD45 1 level was decreased significantly in the moderate infection and under-medication groups in the present study. This is similar to what was observed in previous studies that showed a decline in the level of CD45 1 in severe COVID-19 patients (34, 36) . CD45 1 is an important transmembrane phosphatase involved in T cell activation and signaling (36) . It has been demonstrated that the expression of CD45 1 on T cells was decreased in HIV infection (36) . This suggests that CD45 1 could be used also as an indicator for assessment of the severity of COVID-19 disease (36) . The reduction in T cells, mainly CD4 1 and CD8 1 , is common between severe COVID-19 cases (9). This attribute was also observed in the present study with the moderate infection and under-medication groups, suggesting that there is a relationship between COVID-19 disease severity and the occurrence of lymphopenia (34) . Although lymphopenia is a common feature of many respiratory viral infections, such as human rhinovirus, SARS-CoV, and MERS-CoV, it is more persistent with SARS-CoV-2, likely due to selection of those T cell lineages rather than the other ones. This is by affecting CD4 1 T cells, CD8 1 T cells, B cells, and natural killer cells (9, 20) , a phenomenon found in this study as well. Detection of lymphopenia in COVID-19 patients might thus affect the cell-mediated response, which has a principal role in eliminating viral infection. In addition, lymphopenia affects other immune cells, including B cells, innate immune cells, and natural killer cells. In fact, there was an insignificant difference in the ratio of CD4 1 to CD8 1 T cells between the groups, although CD4 1 and CD8 1 T cells play a vital role in maintaining immune function and viral clearance in the body. This finding was also observed in another study that showed an insignificant difference in the CD4 1 /CD8 1 T cell ratio between COVID-19 patients and healthy individuals (25) . The immunoglobulins IgG and IgM are usually generated by the adaptive immune system in response to infections (37) . IgG and IgM can be specific and serve as diagnostic markers for detecting infections such as COVID-19 (38) . The results of this study showed that the levels of IgG and IgM antibodies are increased in SARS-CoV-2 patients (Fig. 3) . This finding is identical to the results of another group that showed a positive IgG titer in patients infected with SARS-CoV-2 during the first 3 weeks after symptom onset, although IgM showed a slight decrease in the third week (39) . The latter was also observed in our study, as IgM levels started to be generated in the moderate infection and under-mediation groups, and then the levels began to decline in the recovered individuals, suggesting that IgM could be produced first in response to the SARS-CoV-2 infection at the early stage since it can be expressed without isotype switching. Moreover, other studies have reported that IgM levels increased in patients in the first week of infection, with a high peak in the second week prior to a great reduction near background levels in most patients. IgG antibody, on the other hand, was observed after 1 week of infection and was maintained at a high level for a long period of time after the infection occurred (40, 41) . The latter results are similar to what was observed in this study, as IgG levels showed an increase in the moderate stage of infection, reaching the highest level in the recovery stage. High IgG levels were maintained until day 20. This indicates that the patients have developed a humoral immune response against COVID-19 within 7 to 10 days after they have had the infection. Moreover, these results suggest that the IgM antibodies were produced as the body is still infected; however, when the body starts to recover, the IgG antibody starts to be produced, as reported earlier (42) . The production of IgM and IgG antibodies during infection and the increase in IgG in the recovery stage suggest also that IgM and IgG may have neutralized the SARS-CoV-2 and that IgG antibodies created immunity for the body to fight current and future infections. Another study has investigated IgG and IgM responses to SARS-CoV-2 nucleocapsid (N) and spike (S) proteins in severe and nonsevere cases after infection (43) . The study reported that the response of IgM against S and N proteins increases after the onset of symptoms, reaching a peak in the second week of infection in some patients. The response of IgG against N and S proteins, however, continued to increase in the third week in some patients. The response of IgG to S protein was higher in moderate cases in comparison to severe cases in the third week. The response of IgG against N protein, on the other hand, was significantly higher in severe cases, with this difference attributed to the fact that the increase in IgG in response to S protein correlated with a reduction in C-reactive proteins in severely infected patients (43) . In our study, we have noticed a similar pattern where levels of IgG increased considerably. Therefore, it would be interesting to investigate the levels of IgG and IgM in response to N proteins as we have only measured the levels of IgG and IgM against the S protein in this set of patients. Also, quantitative detection of IgG and IgM could help in evaluating the severity of the disease as well as could establish a dynamic that can help in predicting prognosis. In conclusion, our data present the responses of cell-mediated and humoral-mediated immunity in both infected and recovered SARS-CoV-2 patients. The results support the concept of lymphopenia in patients with moderate infection and under medication, as confirmed in other studies (9, 20) . On the other hand, our study confirmed the presence of strong humoral-mediated immunity in the recovered cases. It could be speculated that SARS-CoV-2 infection negatively affected the activation and proliferation of T cells, while the production of antibodies occurred independently of T cells. The latter represents the role of humoral immunity in controlling SARS-CoV-2 infection and in providing the required protection, which may be investigated in future studies for their long-term presence. Furthermore, our results can aid in the future development of SARS-CoV-2 treatments and vaccines. In addition, our results can enhance the discovery of anti-virus-specific T cell clones and the development new immunotherapeutic "weapons" to fight this threatening disease. Blood samples (two tubes from each patient) from patients with confirmed SARS-CoV-2 diagnosis as well as from SARS-CoV-2-negative patients (who had no symptoms of SARS-CoV-2 infection and no identifying information) from the PMAH were utilized in this study. The first fresh blood tube was directly utilized in the flow cytometry experiment. For the ELISA, the serum from the second blood tube was isolated and stored at 280°C until use. Flow cytometry. Each patient's sample was placed in a BD Trucount tube that was labeled with the sample accession number. Ten microliters of BD Multitest 6-color TBNK reagent was added, followed by 50 mL of a well-mixed EDTA-anticoagulated whole-blood sample. The tube was then capped and vortexed gently to be mixed. The sample was incubated for 15 min in the dark at room temperature (20 to 25°C). Thereafter, 450 mL of 1Â BD fluorescence-activated cell sorter (FACS) lysing solution was added. The sample was capped and vortexed gently and then incubated for 10 min in the dark at room temperature (20 to 25°C). The sample should have been acquired within 1 h of lysing. The sample of viable total cells was ready to be analyzed on the flow cytometer. In each sample, the levels that represent the percentages of total cell numbers of CD3 1 /CD3 1 CD4 1 /CD3 1 CD8 1 T cells, CD19 1 B lymphocytes, and CD45 1 cells were calculated for each patient. Analysis was performed using the BD FACSCanto clinical software. ELISA. In order to detect the presence of the spike and nucleocapsid (S and N) proteins of the SARS-CoV-2 virus, commercially available SARS-CoV-2 IgG antibody and SARS-CoV-2 IgM antibody detection kits (from BGI, catalogue no. 0601038 and 0601039, respectively) were used as per the manufacturer's instructions. All reagents were incubated at room temperature for half an hour prior to use. Washing buffer was diluted at a ratio of 1:20 with distilled water. Serum samples were diluted at a ratio of 1:10 in reagent diluent. One hundred microliters of diluted samples was added to each well, along with 100 mL of each positive and negative control. A blank well where no liquid was added was included. The coated plate was incubated at 37°C for 60 min. The plate was then washed five times using 300 mL washing buffer with the assistance of an automated microplate washer (Wellwash; Thermo Fisher). One hundred microliters of the enzyme solution was added to each well, and the plate was incubated at 37°C for 20 min. Thereafter, the plate was washed with washing buffer five times. Then 50 mL of both substrates A and B was added to each well and mixed thoroughly. The plate was incubated at 37°C for 10 min away from light prior to quenching the reaction using 50 mL of stop buffer added to each well. The absorbance was measured immediately at a 450-nm wavelength using a Multiskan microplate reader purchased from Thermo Scientific. Statistical analysis. Statistical analysis was done using RStudio version 1.4.1103 and IBM SPSS 16.0. Correlation and data exploration were performed to understand the variables. ANOVA, which is a collection of methods for comparing multiple means across different groups, was done for all four categories across variables. A post hoc comparison HSD Tukey's test was performed to find the differences between the categories. A two-sided P value of ,0.05 in flow cytometry data and a P value of ,0.001 in ELISA data were considered statistically significant with a 95% confidence level. Supplemental material is available online only. SUPPLEMENTAL FILE 1, PDF file, 0.2 MB. Immune response in COVID-19: what do we currently know? Microb Pathog 148:104484 World Health Organization Different innate and adaptive immune response to SARS-CoV-2 infection of asymptomatic, mild and severe cases A review of coronavirus disease-2019 (COVID-19) Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications The trinity of COVID-19: immunity, inflammation and intervention 2020. T cell responses in patients with COVID-19 Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Impaired cytotoxic CD8 1 T cell response in elderly COVID-19 patients Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome Thymosin alpha-1 protected T cells from excessive activation in severe COVID-19 Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity SARS-CoV-2 infection protects against rechallenge in rhesus macaques Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Increased expression of CD8 marker on T-cells in COVID-19 patients Age-dependent dysregulation of innate immunity Evaluation of nine commercial SARS-CoV-2 immunoassays Evaluation of enzyme-linked immunoassay and colloidal gold-immunochromatographic assay kit for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia (COVID-19) T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4 T cells are important in control of SARS-CoV infection Expanding roles for CD4 1 T cells in immunity to viruses CD4 1 T cells promote humoral immunity and viral control during Zika virus infection Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors Clinical and immunological features of severe and moderate coronavirus disease 2019 CD4 and CD8 lymphocyte counts as surrogate early markers for progression in SARS-CoV-2 pneumonia: a prospective study CD45: a critical regulator in immune cells to predict severe and non-severe COVID-19 patients Natural antibodies bridge innate and adaptive immunity Immune response in COVID-19: a review Antibody responses to SARS-CoV-2 in patients with COVID-19 Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 Patterns of IgG and IgM antibody response in COVID-19 patients Profile of specific antibodies to the SARS-associated coronavirus Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients This work was funded by King Abdulaziz City for Science and Technology for the fast-track Funding Path for COVID-19 Research no. 5-20-01-675-0004. We thank all patients who participated in this study.